| Trial ID: | L4324 |
| Source ID: | NCT01449019
|
| Associated Drug: |
Exendin(9-39)Amide
|
| Title: |
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
DFG_5
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: exendin(9-39)amide|DRUG: saline|OTHER: duodenal meal|OTHER: duodenal saline
|
| Outcome Measures: |
Primary: The incretin effect, The incretin effect is the difference between postprandial plasma concentrations of insulin and C-peptide, respectively, and those during the isoglycemic fasting control experiment. The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion | Secondary: Plasma concentrations of glucagon, The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion|Plasma concentrations of insulin, The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion|Plasma concentrations of C-peptide, The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion|Plasma concentrations of Glucagon-like peptide-1(7-36) (GLP-1(7-36)), The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion|Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP), The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion., Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion
|
| Sponsor/Collaborators: |
Sponsor: Ludwig-Maximilians - University of Munich
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2006-12
|
| Completion Date: |
2010-07
|
| Results First Posted: |
|
| Last Update Posted: |
2011-10-07
|
| Locations: |
Ludwig Maximilians-University, Clinical Research Unit, Munich, 80999, Germany|Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich, 81377, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01449019
|
